42
Participants
Start Date
January 20, 2021
Primary Completion Date
June 28, 2022
Study Completion Date
June 28, 2022
Faster-acting insulin aspart
Faster-acting insulin aspart given as subcutaneous (s.c., under the skin) injections according to routine clinical practice. The decision to initiate treatment with commercially available Fiasp® must be made by the patient and the treating physician before and independently from the decision to include the patient in this study.
Max Super Speciality Hospital, Saket, New Delhi
Dr B L Kapur Memorial Hospital, New Delhi
Sir Ganga Ram Hospital-Cardiology, New Delhi
Post Graduate Institute of Medical Education & Research, Chandigarh
Max Super Speciality Hospital, Mohali, Mohali
Max Super Speciality Hospital, Ghaziabad, Ghaziabad
Regency Hospital, Kanpur
Medanta Lucknow Hospital, Lucknow
Vijayratna Diagnostic & Scientific Obesity Clinic, Ahmedabad
Zandra Healthcare Pvt Ltd, Mumbai
Apollo Hospital, Navi Mumbai, Mumbai
chelleram Diabetes Institute, Pune
Siddhi Hospital And Laparoscopy Center Pvt Ltd, Pune
Excel Endocrine Centre, Kolhāpur
TOTALL Diabetes Hormone Institute, Indore
Life Care Clinic & Research Centre, Bangalore
Mysore Medical College and Research Institute, Mysore
Kg Hospital and Post Graduate Medical Institute, Coimbatore
Aster Medcity, Kochi
Kerala Institute of Medical Sciences, Trivandrum
AMRI Hospitals, Dhakuria, Kolkata
Apollo Multispeciality Hospital, Kolkata, Kolkata
All India Institute of Medical Sciences (AIIMS), Bhubaneswar, Khurda
Santokba Durlabhji Memorial Hospital, Jaipur
Arthur Asirvatham hospital,, Madurai
Jothydev's Diabetes & Research Center, Thriruvananthapuram
Lead Sponsor
Novo Nordisk A/S
INDUSTRY